Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
14 juin 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
08 juin 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Provides Company Update Today
01 juin 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023
30 mai 2023 07h00 HE
|
Plus Therapeutics Inc.
Plus Therapeutics’ partnership with Medidata resulted in a valid historical control arm for the Company’s Phase 1/2 clinical and potential Phase 3 trials evaluating rhenium (186Re) obisbemeda in...
Plus Therapeutics to Present at the 2023 Virtual June Investor Summit
25 mai 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
16 mai 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 16, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics to Present in EndBrainCancer Initiative Virtual Educational Event
12 mai 2023 07h00 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, May 12, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
02 mai 2023 07h00 HE
|
Plus Therapeutics Inc.
New supply agreement includes additional lots of intermediate drug product to support the manufacture of the rhenium (186Re) obisbemeda radiotherapeutic AUSTIN, Texas, May 02, 2023 (GLOBE NEWSWIRE)...
Plus Therapeutics Announces Reverse Stock Split
28 avr. 2023 12h55 HE
|
Plus Therapeutics Inc.
AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced...
Plus Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
20 avr. 2023 16h05 HE
|
Plus Therapeutics Inc.
Plus completes Phase 1/Part A of the ReSPECT-LM trial Management to host conference call today at 5:00 p.m. ET AUSTIN, Texas, April 20, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc....